Topical corticosteroids and the risk of diabetes mellitus: A nested case-control study in the Netherlands

Drug Safety

Volumn 32, Issue 6, 2009, Pages 527-537

  Van Der Linden, Michiel W ^a   Penning Van Beest, Fernie J A ^a   Nijsten, Tamar ^b   Herings, Ron M C ^a,b  

^a PHARMO INSTITUTE FOR DRUG OUTCOMES RESEARCH   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTICONVULSIVE AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; FLUTICASONE; NEUROLEPTIC AGENT; THIAZIDE DIURETIC AGENT;

ADULT; AGED; ARTICLE; ATOPIC DERMATITIS; CASE CONTROL STUDY; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG EFFECT; DRUG POTENCY; DRUG SAFETY; FEMALE; FOLLOW UP; GENERAL PRACTITIONER; GLUCOSE METABOLISM; HOSPITALIZATION; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NETHERLANDS; PHARMACOEPIDEMIOLOGY; PRESCRIPTION; PRIORITY JOURNAL; QUESTIONNAIRE; REGRESSION ANALYSIS; RISK ASSESSMENT; SKIN ATROPHY;

ADMINISTRATION, TOPICAL; ADRENAL CORTEX HORMONES; ADULT; AGED; CASE-CONTROL STUDIES; DIABETES MELLITUS; FEMALE; HUMANS; MALE; MIDDLE AGED; NETHERLANDS; RISK;

EID: 66249138134     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200932060-00008     Document Type: Article

References (40)

1. Carruthers JA, August PJ, Staughton RC. Observations on the systemic effect of topical clobetasol propionate (Dermovate). Br Med J 1975; 4 (5990): 203-4
2. Nilsson JE, Gip LJ. Systemic effects of local treatment with high doses of potent corticosteroids in psoriatics. Acta Derm Venereol 1979; 59 (3): 245-8
3. Levin C, Maibach HI. Topical corticosteroid-induced adrenocortical insufficiency: clinical implications. Am J Clin Dermatol 2002; 3 (3): 141-7
4. Abma EM, Blanken R, De Heide LJ. Cushing's syndrome caused by topical steroid therapy for psoriasis. Neth J Med 2002; 60 (3): 148-50
5. Gilbertson EO, Spellman MC, Piacquadio DJ, et al. Super potent topical corticosteroid use associated with adrenal suppression: clinical considerations. J Am Acad Dermatol 1998; 38 (2 Pt 2): 318-21
6. Weber SL. Cushing's syndrome attributable to topical use of lotrisone. Endocr Pract 1997; 3 (3): 140-4
7. Reynolds RM, Syddall HE, Walker BR, et al. Predicting cardiovascular risk factors from plasma cortisol measured during oral glucose tolerance tests. Metabolism 2003; 52 (5): 524-7
8. Poa NR, Edgar PF. Insulin resistance is associated with hypercortisolemia in Polynesian patients treated with antipsychotic medication. Diabetes Care 2007; 30 (6): 1425-9
9. Sasaki N, Iwase M, Arima H, et al. Overt diabetes mellitus in a patient with combined primary aldosteronism and Cushing's syndrome. Intern Med 2006; 45 (21): 1237-42
10. Aalto-Korte K, Turpeinen M. Quantifying systemic absorption of topical hydrocortisone in erythroderma. Br J Dermatol 1995; 133 (3): 403-8
11. Dekhuijzen PN, Honour JW. Inhaled corticosteroids and the hypothalamic-pituitary-adrenal (HPA) axis: do we understand their interaction? Respir Med 2000; 94 (7): 627-31
12. Barnes N. The properties of inhaled corticosteroids: similarities and differences. Prim Care Resp J 2007; 16 (3): 149-54
13. Dendukuri N, Blais L, LeLorier J. Inhaled corticosteroids and the risk of diabetes among the elderly. Br J Clin Pharmacol 2002; 54 (1): 59-64
14. Blackburn D, Hux J, Mamdani M. Quantification of the risk of corticosteroid-induced diabetes mellitus among the elderly. J Gen Intern Med 2002; 17 (9): 717-20
15. Gulliford MC, Charlton J, Latinovic R. Risk of diabetes associated with prescribed glucocorticoids in a large population. Diabetes Care 2006; 29 (12): 2728-9
16. Gomez EC, Frost P. Induction of glycosuria and hyperglycemia by topical corticosteroid therapy. Arch Dermatol 1976; 112(11): 1559-62
17. Sobngwi E, Lubin V, Ury P, et al. Adrenal insufficiency and diabetes mellitus secondary to the use of topical corticosteroids for cosmetic purpose. Ann Endocrinol (Paris) 2003; 64 (3): 202-4
18. Delea TE, Gokhale M, Makin C, et al. Administrative claims analysis of utilization and costs of care in health plan members with atopic dermatitis who had prior use of a topical corticosteroid and who initiate therapy with pime-crolimus or tacrolimus. J Manag Care Pharm 2007; 13 (4): 349-59
19. CDC National Center for Health Statistics. International classification of diseases. 9th rev., clinical modification (ICD-9-CM) [online]. Available from URL: http://www. cdc.gov/nchs/about/otheract/icd9/abticd9.htm [Accessed 2009 Mar 31]
20. Herings RM. PHARMO: a record linkage system for post-marketing surveillance of prescription drugs in The Netherlands [dissertation]. Utrecht: Utrecht University, Department of Pharmaco-epidemiology and Pharmaco-therapy, 1993
21. Hodari KT, Nanton JR, Carroll CL, et al. Adherence in dermatology: a review of the last 20 years. J Dermatolog Treat 2006; 17(3): 136-42
22. Herings RMC, de Jong R, on behalf of the PHARMO Institute for Drug Outcomes Research. Market exploration report: topical corticosteroids [in Dutch]. Utrecht: PHARMO Institute for Drug Outcomes Research, 2004
23. Furue M, Terao H, Rikihisa W, et al. Clinical dose and adverse effects of topical steroids in daily management of atopic dermatitis. Br J Dermatol 2003; 148 (1): 128-33
24. Koro CE, Fedder DO, L'Italien GJ, et al. Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. BMJ 2002; 325 (7358): 243
25. Citrome LL, Jaffe AB. Relationship of atypical anti-psychotics with development of diabetes mellitus. Ann Pharmacother 2003; 37 (12): 1849-57
26. Feldman SR, Camacho FT, Krejci-Manwaring J, et al. Adherence to topical therapy increases around the time of office visits. J Am Acad Dermatol 2007; 57 (1): 81-3
27. Vlaski E, Stavric K, Isjanovska R, et al. Overweight hypothesis in asthma and eczema in young adolescents. Allergol Immunopathol (Madr) 2006; 34 (5): 199-205
28. Setty AR, Curhan G, Choi HK. Obesity, waist circumference, weight change, and the risk of psoriasis in women: Nurses' Health Study II. Arch Intern Med 2007; 167 (15): 1670-5
29. Boehncke S, Thaci D, Beschmann H, et al. Psoriasis patients show signs of insulin resistance. Br J Dermatol 2007; 157 (6): 1249-51
30. Salas M, Hofman A, Stricker BH. Confounding by indication: an example of variation in the use of epidemiologic terminology. Am J Epidemiol 1999; 149 (11): 981-3
31. Atherton DJ. Topical corticosteroids in atopic dermatitis. BMJ 2003; 327 (7421): 942-3
32. Hoare C, Li Wan Po A, Williams H. Systematic review of treatments for atopic eczema. Health Technol Assess 2000; 4(37): 1-191
33. Callen J, Chamlin S, Eichenfield LF. A systematic review of the safety of topical therapies for atopic dermatitis. Br J Dermatol 2006; 152 (2): 1-19
34. Bruner CR, Feldman SR, Ventrapragada M, et al. A systematic review of adverse effects associated with topical treatments for psoriasis. Dermatol Online J 2003; 9 (1): 2
35. Van Der Meer JB, Glazenburg EJ, Mulder PG, et al. The management of moderate to severe atopic dermatitis in adults with topical fluticasone propionate. The Netherlands Adult Atopic Dermatitis Study Group. Br J Dermatol 1999; 140(6): 1114-21
36. Berth-Jones J, Damstra RJ, Golsch S, et al. Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis: randomised, double blind, parallel group study. BMJ 2003; 326(7403): 1367
37. Boukes FS, Wiersma T, Cleveringa JP, et al. Summary of the practice guideline 'atopic dermatitis' (first revision) from the Dutch College of General Practitioners. Ned Tijdschr Geneeskd 2007; 151 (25): 1394-8
38. Bruijnzeel-Koomen CA, Sillevis Smitt JH, Boukes FS, et al. The practice guideline 'atopic dermatitis'. Ned Tijdschr Geneeskd 2007; 151 (25): 1399-402
39. Charman CR, Morris AD, Williams HC. Topical cortico-steroid phobia in patients with atopic eczema. Br J Dermatol 2000; 142 (5): 931-6
40. Charman C, Williams H. The use of corticosteroids and corticosteroid phobia in atopic dermatitis. Clin Dermatol 2003; 21 (3): 193-200